COMPARE · Data as of August 14, 2026
AZN vs ETON
Verdict: Side-by-side breakdown using the Bull Rankings model. AZN scored 75.4, ETON scored 72.0 — AZN leads.
Compare another set
Different reporting periods. ETON's fundamentals are as of June 2026, but AZN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
AZN
AstraZeneca PLC
75.4
$156.45 · $242.6B
fundamentals as of
Score gap
3.4
AZN leads
ETON
Eton Pharmaceuticals, Inc.
72
$58.86 · $1.7B
fundamentals as of
The model, pillar by pillar (0–100 each)
AZN
stronger →← stronger
ETON
78
Qualityreturns · margins · balance sheet
76
78
Growthrevenue & earnings expansion
100
70
Valuevaluation vs sector peers
50
AZN is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AZN
ETON
$11.8bA-
FCF
$15mC-
+8.6%B
Rev
+81.5%A
0.64C+
D/E
1.02C
23.4xB+
P/E
150.9xD
1.37B
PEG
1.40B
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
AZN
ETON
8% above
Price vs fair valuelower is cheaper
335% above
~11%/yr
Growth the price implies10-yr FCF · lower = less priced in
~54%/yr
-20%
1-yr DCF upside
-83%
-8%
5-yr DCF upside
-77%
+15%
10-yr DCF upside
-65%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AZN
Why this score
- Raising its dividend
ETON
Why this score
- Short track record
The companies
AZNAstraZeneca PLC
Why now
Drug Manufacturers - General · market cap $242.6b. Down 26% from 52-week high of $212.71 — deep drawdown territory. 10 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $213.69 (implying +37% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 21% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 115% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ETONEton Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Trading near 52-week high of $59.69 — momentum setup, limited technical margin of safety. Revenue growing +81% — in hypergrowth territory. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.33 (implying +6% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 116% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 150.9x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. P/S 15.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AZN and ETON diverge
On the headline score the gap is 3.4 points in favor of AZN. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- GrowthAZN 78.5 · ETON 100.0ETON +21.5
- ValueAZN 70.0 · ETON 50.0AZN +20.0
- QualityAZN 78.1 · ETON 75.6level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.